Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C

References

• Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age‐specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–1342.
   PubMed Web of Science ®Google Scholar
• Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–176.
   PubMed Web of Science ®Google Scholar
• Ayoub HH, Chemaitelly H, Omori R, et al. Hepatitis C virus infection spontaneous clearance: has it been underestimated? Inter J Infect Dis. 2018;75:60–66.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Comarmond C, Domont F, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016;3(1):3–14.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Zignego AL, Ferri C, et al. Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J Hepatol. 2017;66(6):1282–1299.
   PubMed Web of Science ®Google Scholar
• Nicolini LA, Zappulo E, Viscoli C, et al. Management of chronic viral hepatitis in the hematological patient. Expert Rev Anti Infect Ther. 2018;16(3):227–241.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheumatism. 1999;42(10):2204–2212.
   PubMed Web of Science ®Google Scholar
• Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nature Rev Microbiol. 2007;5(6):453.
   PubMed Web of Science ®Google Scholar
• Rice CM. New insights into HCV replication: potential antiviral targets. Top Antivir Med. 2011;19(3):117.
   PubMedGoogle Scholar
• Gish RG, Meanwell NA. The NS5A replication complex inhibitors: difference makers? Clin Liver Dis. 2011;15(3):627–639.
   PubMed Web of Science ®Google Scholar
• Legrand-Abravanel F, Nicot F, Izopet J. New NS5B polymerase inhibitors for hepatitis C. Expert Opin Investig Drugs. 2010;19(8):963–975.
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Coppola C, et al. Efficacy of the “first wave” Direct acting antivirals against HCV infection: results from the Italian LINA (Liver Network Activity) cohort. New Microbiol. 2019;42(2):94–100.
   PubMed Web of Science ®Google Scholar
• Gentile I, Scotto R. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort). Hepatol Int. 2019;13(1):66–74.
   PubMed Web of Science ®Google Scholar
• Kondili LA, Gaeta GB, Brunetto MR, et al. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: interim evaluations from the PITER network. PloS One. 2017;12(10):e0185728.
   PubMed Web of Science ®Google Scholar
• Hezode C. Treatment of hepatitis C: results in real life. Liver Int. 2018;38(Suppl 1):21–27.
   PubMedGoogle Scholar
• Ioannou GN, Feld JJ. What are the benefits of a sustained virologic response to direct-acting antiviral therapy for Hepatitis C virus infection? Gastroenterology. 2019;156(2):446–460.e442.
   PubMed Web of Science ®Google Scholar
• Kiser JJ, Flexner C. Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427–449.
   PubMed Web of Science ®Google Scholar
• De Clercq E. Current race in the development of DAAs (direct-acting antivirals) against HCV. Biochem Pharmacol. 2014;89(4):441–452.
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia F, Zappulo E, et al. Efficacy and safety of sofosbuvir in the treatment of chronic hepatitis C: the dawn of a new era. Rev Recent Clin Trials. 2014;9(1):1–7.
   PubMedGoogle Scholar
• Gentile I, Maraolo AE, Buonomo AR, et al. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opin Drug Discov. 2015;10(12):1363–1377.
   PubMed Web of Science ®Google Scholar
• Schinazi R, Halfon P, Marcellin P, et al. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014;34(Suppl 1):69–78.
   PubMed Web of Science ®Google Scholar
• Ahmed AM, Doheim MF. Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis. J Med Virol. 2018;90(5):907–918.
   PubMed Web of Science ®Google Scholar
• Gentile I, Coppola N, Buonomo AR, et al. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opin Investig Drugs. 2014;23(9):1211–1223.
   PubMed Web of Science ®Google Scholar
• Gentile I, Scotto R, Zappulo E, et al. Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. Expert Opin Investig Drugs. 2016;25(5):557–572.
   PubMed Web of Science ®Google Scholar
• Dammacco F, Lauletta G, Russi S, et al. Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. Clin Exp Med. 2019;19(1):1–21.
   PubMed Web of Science ®Google Scholar
• Li DK, Chung RT. Overview of direct-acting antiviral drugs and drug resistance of hepatitis C virus. Methods Mol Biol. 2019;1911:3–32.
   PubMedGoogle Scholar
• Pol S, Parlati L. Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in “special populations”. Liver Int. 2018;38(Suppl 1):28–33.
   PubMed Web of Science ®Google Scholar
• Sikavi C, Najarian L, Saab S. Similar sustained virologic response in real-world and clinical trial studies of hepatitis C/human immunodeficiency virus coinfection. Dig Dis Sci. 2018;63(11):2829–2839.
   PubMed Web of Science ®Google Scholar
• Ekpanyapong S, Reddy KR. Hepatitis C virus therapy in advanced liver disease: outcomes and challenges. United European Gastroenterol J. 2019;7(5):642–650.
   PubMed Web of Science ®Google Scholar
• Persico M, Aglitti A, Caruso R, et al. Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin’s lymphoma. Hepatology. 2018;67(1):48–55.
   PubMed Web of Science ®Google Scholar
• Marcellusi A, Viti R, Kondili LA, et al. Economic consequences of investing in anti-HCV antiviral treatment from the Italian NHS perspective: a real-world-based analysis of PITER data. PharmacoEconomics. 2019;37(2):255–266.
   PubMed Web of Science ®Google Scholar
• WHO. Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries, March 2018. Geneva, Switzerland: World Health Organization; 2018 (WHO/CDS/HIV/18.4). Licence: CC BY-NC-SA 3.0 IGO. (Ed.^(Eds); 2018. [cited 2019 Nov 11]. Available from: https://apps.who.int/iris/bitstream/handle/10665/260445/WHO-CDS-HIV-18.4-eng.pdf?sequence=1&isAllowed=y
   Google Scholar
• Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34–44.
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia F, Coppola N, et al. Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A. Curr Med Chem. 2014;21(12):1391–1404.
   PubMed Web of Science ®Google Scholar
• Stedman CA. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol. 2013;28(1):38–45.
   PubMed Web of Science ®Google Scholar
• Gallay PA, Lin K. Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des Devel Ther. 2013;7:105–115.
   PubMed Web of Science ®Google Scholar
• Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int. 2012;32(Suppl 1):88–102.
   PubMed Web of Science ®Google Scholar
• Borgia G, Maraolo AE, Buonomo AR, et al. The therapeutic potential of new investigational hepatitis C virus translation inhibitors. Expert Opin Investig Drugs. 2016;25(10):1209–1214.
   PubMed Web of Science ®Google Scholar
• Sandmann L, Schulte B, Manns MP, et al. Treatment of chronic hepatitis C: efficacy, side effects and complications. Visc Med. 2019;35(3):161–170.
   PubMed Web of Science ®Google Scholar
• Smolders EJ, Jansen AME, Ter Horst PGJ. Viral Hepatitis C THERAPY: PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS: A 2019 UPDAte. Clin Pharmacokinet. 2019;58(10):1237–1263.
   PubMed Web of Science ®Google Scholar
• Zajac M, Muszalska I, Sobczak A, et al. Hepatitis C - New drugs and treatment prospects. Clin Pharmacokinet. 2019;165:225–249.
   Google Scholar
• Vermehren J, Park JS, Jacobson IM, et al. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol. 2018;69(5):1178–1187.
   PubMed Web of Science ®Google Scholar
• Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465(7294):96–100.
   PubMed Web of Science ®Google Scholar
• Guedj J, Dahari H, Rong L, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A. 2013;110(10):3991–3996.
   PubMed Web of Science ®Google Scholar
• Manolakopoulos S, Zacharakis G, Zissis M, et al. Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C. Ann Gastroenterol. 2016;29(3):282–296.
   PubMed Web of Science ®Google Scholar
• Gentile I, Carleo MA, Borgia F, et al. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs. 2010;19(1):151–159.
   PubMed Web of Science ®Google Scholar
• Scola PM, Sun LQ, Wang AX, et al. The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014;57(5):1730–1752.
   PubMed Web of Science ®Google Scholar
• Yan Y, Li Y, Munshi S, et al. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci. 1998;7(4):837–847.
   PubMed Web of Science ®Google Scholar
• Germain MA, Chatel-Chaix L, Gagne B, et al. Elucidating novel hepatitis C virus/host interactions using combined mass spectrometry and functional genomics approaches. Mol Cell Proteomics. 2013;29:29.
   Google Scholar
• McPhee F, Sheaffer AK, Friborg J, et al. Preclinical profile and characterization of the hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother. 2012;56(10):5387–5396.
   PubMed Web of Science ®Google Scholar
• Kukolj G, McGibbon GA, McKercher G, et al. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem. 2005;280(47):39260–39267.
   PubMed Web of Science ®Google Scholar
• Tomei L, Altamura S, Bartholomew L, et al. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Virol. 2003;77(24):13225–13231.
   PubMed Web of Science ®Google Scholar
• Rigat KL, Lu H, Wang YK, et al. Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase. J Biol Chem. 2014;289(48):33456–33468.
   PubMed Web of Science ®Google Scholar
• Sofia MJ, Chang W, Furman PA, et al. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase. J Med Chem. 2012;55(6):2481–2531.
   PubMed Web of Science ®Google Scholar
• Lemm JA, Liu M, Gentles RG, et al. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother. 2014;58(6):3485–3495.
   PubMed Web of Science ®Google Scholar
• Pelosi LA, Voss S, Liu M, et al. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother. 2012;56(10):5230–5239.
   PubMed Web of Science ®Google Scholar
• Friborg J, Zhou N, Han Z, et al. In vitro assessment of re-treatment options for patients with hepatitis C virus genotype 1b infection resistant to daclatasvir plus asunaprevir. Infect Dis Ther. 2014. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• PMDA. Review Report on Ximency Combination Tablets. (Ed.^(Eds). Pharmaceuticals and Medical Devices Agency. 2016,1–94. [cited 2019 Nov 11]. Available from: http://www.pmda.go.jp/files/000226231.pdf
   Google Scholar
• Garimella T, Tao X, Sims K, et al. Effects of a fixed-dose co-formulation of daclatasvir, asunaprevir, and beclabuvir on the pharmacokinetics of a cocktail of cytochrome P450 and drug transporter substrates in healthy subjects. Drugs R D. 2018;18(1):55–65.
   PubMed Web of Science ®Google Scholar
• Everson GT, Sims KD, Rodriguez-Torres M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology. 2014;146(2):420–429.
   PubMed Web of Science ®Google Scholar
• Wang X, Li W, Huang SP, et al. Evaluation of pharmacokinetic Drug–drug Interaction (DDI) between BMS-791325, an NS5B non-nucleotide polymerase inhibitor, daclatasvir and asunaprevir in triple combination in HCV genotype 1-infected patients. Poster 451. J Hepatol. 2013;58(58):S63–S227.
   Google Scholar
• Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4(8):1065–1074.
   PubMed Web of Science ®Google Scholar
• Adamczyk R, Sims K, Hesney M, et al. The Effect of Renal Impairment on Multiple-dose Pharmacokinetics of the Fixed-dose Combination of Daclatasvir/Asunaprevir/Beclabuvir. In: EASL-50th International Liver Congress; 2015. P0790. (Ed.^(Eds); Vienna.
   Google Scholar
• Osawa M, Ueno T, Shiozaki T, et al. Population pharmacokinetic analysis of daclatasvir, asunaprevir, and beclabuvir combination in HCV-infected subjects. Clin Pharmacol Drug Dev. 2019;8(6):802–817.
   PubMed Web of Science ®Google Scholar
• Everson GT, Thuluvath PJ, Lawitz E, et al. All-Oral Combination of Daclatasvir, Asunaprevir, and BMS-791325 for HCV Genotype 1 Infection. In: Conference on Retroviruses and Opportunistic Infections (CROI); March 3–6, 2014; Boston, MA. Oral 25; 2014; Boston, MA(Ed.^(Eds).
   Google Scholar
• Everson G, Sims KD, Thuluvath PJ, AL. Daclatasvir in combination with asunaprevir and beclabuvir for prior null responders with chronic HCV genotype 1 infection. Poster presented at: . In: The Liver Meeting® 2014, the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7–11, 2014; Poster 1943; 2014; Boston, MA.. (Ed.^(Eds).
   Google Scholar
• Hassanein T, Sims KD, Bennett M, et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic Hepatitis C Virus Genotype 4 infection. J Hepatol. 2015;62(5):1204–1206.
   PubMed Web of Science ®Google Scholar
• Poordad F, Sievert W, Mollison L All-oral, fixed-dose combination therapy with daclatasvir/asunaprevir/beclabuvir for non-cirrhotic patients with chronic HCV genotype 1 infection: UNITY-1 phase 3 SVR12 results. Poster presented at:. In: The Liver Meeting 2014, the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7–11, 2014; Poster LB-7; 2014; Boston, MA. Ed.^(Eds).
   Google Scholar
• Muir A, Poordad F, Lalezari J, et al. All-oral fixed-dose combination therapy with daclatasvir/asunaprevir/beclabuvir, ± ribavirin, for patients with chronic HCV genotype 1 infection and compensated cirrhosis: UNITY-2 phase 3 SVR12 results. Oral presentation. In: The Liver Meeting® 2014, the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7–11, 2014; Oral LB-2; 2014; Boston, MA.
   Google Scholar
• Toyota J, Karino Y, Suzuki F, et al. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection. J Gastroenterol. 2017;52(3):385–395.
   PubMed Web of Science ®Google Scholar
• Kao JH, Yu ML. Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1. J Gastroenterol Hepatol. 2017;32(12):1998–2005.
   PubMed Web of Science ®Google Scholar
• Takaguchi K, Toyoda H, Tsutsui A, et al. Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan. J Gastroenterol. 2019;54(8):742–751.
   PubMed Web of Science ®Google Scholar
• Gentile I, Zappulo E, Buonomo AR, et al. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs. 2015;24(8):1111–1121.
   PubMed Web of Science ®Google Scholar
• Teraoka Y, Uchida T, Imamura M, et al. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure. Hepatol Commun. 2018;99(8):1058–1065.
   Google Scholar
• Everson GT, Sims KD, Thuluvath PJ, et al. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients. Liver Int. 2016;36(2):189–197.
   PubMed Web of Science ®Google Scholar
• Ueno T, Osawa M, Shiozaki T, et al. Exposure-response analysis for efficacy of daclatasvir, asunaprevir, and beclabuvir combinations in HCV-infected patients. Clin Pharmacol Drug Dev. 2019 Oct;8(7):903–913.
   Web of Science ®Google Scholar
• McPhee F, Hernandez D, Zhou N, et al. Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir. J Med Virol. 2018;23(1):53–66.
   Google Scholar
• Osawa M, Ueno T, Shiozaki T, et al. Safety exposure-response analysis for daclatasvir, asunaprevir, and beclabuvir combinations in HCV-infected subjects. J Clin Pharmacol. 2019;59(4):557–565.
   PubMed Web of Science ®Google Scholar
• PMDA. Summary of investigation results- asunaprevir, daclatasvir hydrochloride, daclatasvir hydrochloride/asunaprevir/beclabuvir hydrochloride. (Ed.^(Eds). Pharmaceuticals and Medical Devices Agency; 2019.[cited 2019 Nov 11]. Available from: https://www.pmda.go.jp/files/000227481.pdf
   Google Scholar
• Shrivastava S, Bhatta M, Ward H, et al. Multitarget direct-acting antiviral therapy is associated with superior immunologic recovery in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatol Commun. 2018;2(12):1451–1466.
   PubMed Web of Science ®Google Scholar
• BMS. Real-world incidence proportion of hepatic toxicity and All Adverse Drug Reactions (ADRs) in Japanese patients receiving daclatasvir (DCV) trioTherapy. (Ed.Bristol-Myers Squibb). [cited 2019 Oct 26]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03071133
   Google Scholar
• Buonomo AR, Scotto R, Pinchera B, et al. Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy. New Microbiol. 2018;41(1):26–29.
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Zappulo E, et al. Discontinued drugs in 2012–2013: hepatitis C virus infection. Expert Opin Investig Drugs. 2015;24(2):239–251.
   PubMed Web of Science ®Google Scholar
• Baumert TF, Berg T, Lim JK, et al. Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges. Gastroenterology. 2019;156(2):431–445.
   PubMed Web of Science ®Google Scholar
• WHO. Hepatitis C-Key facts; 2019. (Ed.^(Eds). [cited 2019 Nov 11]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
   Google Scholar
• Trademarkia. XIMENCY Trademark Information-Bristol-Myers Squibb Company. (Ed.^(Eds). LegalForce, Inc.; 2017. [cited 2019 Nov 11]. Available from: https://trademark.trademarkia.com/ximency-87656218.html
   Google Scholar